Systematic review of the effects of maternal hypertension in pregnancy and antihypertensive therapies on child neurocognitive development

Reproductive Toxicology

Volumn 39, Issue , 2013, Pages 1-5

  Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Child development; Hypertension; IQ; Labetalol; Methyldopa; Neuro behavioral development; Nifedipine; Pregnancy

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; LABETALOL; METHYLDOPA; NIFEDIPINE;

APGAR SCORE; BEHAVIOR DISORDER; CHILD BEHAVIOR; CHILD DEVELOPMENT; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; FETUS RISK; HEAD CIRCUMFERENCE; HIGH RISK INFANT; HUMAN; INTELLIGENCE QUOTIENT; LONG TERM EXPOSURE; MATERNAL HYPERTENSION; OUTCOME ASSESSMENT; PREECLAMPSIA; PRENATAL DRUG EXPOSURE; PROGENY; REVIEW; RISK ASSESSMENT; SMALL FOR DATE INFANT; SYSTEMATIC REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD DEVELOPMENT; COGNITION; FEMALE; HUMANS; HYPERTENSION; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 84876731441     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2013.03.006     Document Type: Review

References (22)

1. Haddad B., Sibai B.M. Chronic hypertension in pregnancy. Annals of Medicine 1999, 31:246-252.
2. Livingston C.J., Sibai B.M. Chronic hypertension in pregnancy. Obstetrics and Gynecology Clinics of North America 2001, 28:447-463.
3. McCowan L.M., Buist R.G., North R.A., Gamble G. Perinatal morbidity in chronic hypertension. British Journal of Obstetrics and Gynaecology 1996, 103:123-129.
4. Sibai B.M. Chronic hypertension in pregnancy. Obstetrics and Gynecology 2002, 100:369-377.
5. Dennis A.T. Management of pre-eclampsia: issues for anaesthetists. Anaesthesia 2012, 67:1009-1020.
6. Ray J.G., Vermeulen M.J., Burrows E.A., Burrows R.F. Use of antihypertensive medications in pregnancy and the risk for adverse perinatal outcomes: Mc Master Outcome study of hypertension in pregnancy. BMC Pregnancy and Childbirth 2001, 1:6.
7. Ounsted M., Cockburn J., Moar V.A., Redman C.W. Maternal hypertension with superimposed pre-eclampsia: effects on child development at 71/2 years. British Journal of Obstetrics and Gynaecology 1983, 90(July (7)):644-649.
8. Robinson M., Mattes E., Oddy W.H., de Klerk N.H., Li J., McLean N.J., et al. Hypertensive diseases of pregnancy and the development of behavioral problems in childhood and adolescence: the Western Australian Pregnancy CohortStudy. Journal of Pediatrics 2009, 154(February):218-224.
9. Whitehouse A.J., Robinson M., Newnham J.P., Pennell C.E. Do hypertensive diseases of pregnancy disrupt neurocognitive development in offspring?. Paediatric and Perinatal Epidemiology 2012, 26(March (2)):101-108.
10. Tuovinen S., Raikkonen K., Kajantie E., Henriksson M., Liskinen J.T., Pesonen A.K., et al. Hypertensive disorders in pregnancy and cognitive decline in the offspring up to old age. Neurology 2012, 79:1578-1582.
11. Mutch L.M., Moar V.A., Ounsted M.K., Redman CW Hypertension during pregnancy, with and without specific hypotensive treatment. II. The growth and development of the infant in the first year of life. Early Human Development 1977, 1:59-67.
12. Cockburn J., Moar V.A., Ounsted M., Redman CW Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet 1982, 1(March (8273)):647-649.
13. Bortolus R., Ricci E., Chatenoud L., Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG 2000, 107(June (6)):792-794.
14. Koren G., Pastuszak A., Ito S. Drugs in pregnancy. New England Journal of Medicine 1998, 338:1128-1137.
15. Chan W.S., Koren G., Barrera M., Rezvani M., Knittel-Keren D., Nulman I. Neurocognitive development of children following in-utero exposure to labetalol for maternal hypertension: a cohort study using a prospectively collected database. Hypertension in Pregnancy 2010, 29(3):271-283.
16. Nash K., Sheard E., Rovet J., Koren G. Understanding fetal alcohol spectrum disorders (FASDs): toward identification of a behavioral phenotype. Scientific World Journal 2008, 8(September (21)):873-882.
17. Voss W., Jungmann T., Wachtendorf M., Neubauer A.P. Long-term cognitive outcomes of extremely low-birth-weight infants: the influence of the maternal educational background. Acta Paediatrica 2012, 101(June (6)):569-573.
18. Magee L.A., Abalos E., von Dadelszen P., Sibai B., Walkinshaw S.A. Control of hypertension in pregnancy. Current Hypertension Reports 2009, 11(December):429-436. CHIPS Study Group.
19. Baschat A.A. Neurodevelopment following fetal growth restriction and its relationship with antepartum parameters of placental dysfunction. Ultrasound in Obstetrics and Gynecology 2011, 37:501-514.
20. Dragun D., Philippe A. From mother to child-transplacental effect of AT1R-AA in preeclampsia. Nephrology, Dialysis, Transplantation 2010, 25:1774-1776.
21. Irani R.A., Zhang Y., Blackwell S.C. The detrimental role of angiotentin receptor antagonist antibodies in intrauterine growth restriction seen in preeclampsia. Journal of Experimental Medicine 2009, 206:2809-2822.
22. Li D.K., Yang C., Andrade S., Tavares V., Ferber J.R. Maternal exposure to angiotensin converting enzyme inhibitors in the first trimester and risk of malformations in offspring: a retrospective cohort study. British Medical Journal 2011, 343:d5931.